UNSPSC 51294516: Altanserin tartrate

This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P204CHE8J, chemically known as 4(1h)-quinazolinone, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-, (r-(r*,r*))-2,3-dihydroxybutanedioate but more generally known as altanserin tartrate, which bears US NIH Compound Identifier 3033676. Most nations, for tariff and trade purposes, schedule altanserin tartrate under HS 29335995 and SITC 51576.

As of Q4 2014, ALTANSERIN TARTRATE remains US FDA's Preferred Term for this commodity. Altanserin tartrate bears US NLM identifiers UMLS ID C2698070 and NCI Concept Code C79965. SMILES: C1CCC2C(C1)C(=O)N(C(=S)[NH]2)CCN3CCC(CC3)C(=O)C4CCC(CC4)F.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51294516 Altanserin tartrate is a Commodity code that, based on recent state and local procurement activity, describes pharmaceutical and therapeutic products purchased by health authorities and public health agencies to support community health initiatives and pharmacy benefit programs. The issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission and Minnesota Department of Administration represent recent active buyers. The scope of work covers procurement of pharmaceutical products—including controlled-substance alternatives such as naloxone, generic multi-source pharmaceuticals, and over-the-counter products—with delivery and supply-chain compliance requirements including FDA certification, Good Manufacturing Practices compliance, Drug Supply Chain Security Act adherence, and wholesaler relationships.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023, on a two-year term with optional one-year renewal. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and maintain insurance coverage including $5,000,000 commercial general liability per occurrence.